Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
11,067 total articles
Futu (FUTU) has been pummeled by regulatory headlines and class-action filings tied to a May 22, 2026 crackdown on cross-border securities solicitation. That pain looks largely priced in: the stock trades at $95.09 with a market cap near $12.5B, a PE of ~11 and a 2.55% yield. With ECM and enterprise service initiatives beginning to show traction an…
TSS, Inc. is a small-cap integrator for data-center and mission-critical facilities that has pulled revenue and EBITDA higher as AI customers push capacity and require on-site integration. With recent quarterly momentum and 2026 adjusted EBITDA guidance of $20-22M, TSS is positioned to re-rate if execution continues. This trade outlines a mid-term …
Travere (TVTX) now looks like more than a single-product biotech. With Filspari (sparsentan) gaining traction in rare kidney indications and a market cap of ~$5.3B, the setup favors a long-biased trade for patient, risk-aware investors. This idea lays out a clear entry, stop and target, and the reasons to own TVTX over the next 180 trading days.
Versigent (VGNT) combines proprietary electrical architecture for vehicles with exposure to energy storage and electrification trends. At $40.16 and a market cap near $2.9B, the shares trade at an attractive P/E (~5.4) while technicals show near-term weakness. For disciplined traders, a long swing position sized around a mid-risk allocation offers …
Kraft Heinz (KHC) looks attractive as a dividend-oriented, value trade. The stock yields ~6.4%, trades below book at ~0.72x, and is supported by bullish technicals (price > 10/20/50-day averages, RSI ~65, MACD positive). Free cash flow covers the dividend comfortably. We'll lay out an actionable entry, stop and target with a 180-trading-day positio…
National Health Investors (NHI) is a cash-generative REIT focused on senior housing and medical assets. With a 4.75% yield, stable free cash flow, and technical momentum, NHI offers a pragmatic long trade: buy at $77.00, target $88.00, stop $70.00. The trade banks on accelerating senior-housing demand, steady dividend support, and a reasonable valu…
Sibanye Stillwater (SBSW) offers a mid-term swing opportunity. The shares trade near $9 on a flattened post-rally pullback, with a $6.34B market cap, a 2.8% yield and clear catalysts from a potent platinum rally and cost discipline. Technicals and short interest show limited downside pressure; I recommend a defined-entry long with a $13.50 target a…
KeyCorp's May repurchase authorization and steady dividend make the bank an attractive income-plus-capital-gain trade. At around $23, the shares price in modest multiples (P/E ~13.8, P/B ~1.24) while free cash flow and a sensible balance sheet support buybacks and dividends. This trade targets upside from repurchase execution and event-driven clari…
Insulet’s Omnipod franchise remains a durable growth engine despite a manufacturing recall that reset sentiment. At $164.58 the stock prices in a premium multiple (P/E ~37, P/S ~3.8) but also delivers strong free cash flow ($399.9m) and high returns on equity (23%). For traders who want exposure to recovery in device adoption, a controlled long wit…
PagSeguro’s mix of low-risk deposits, merchant POS hardware and growing digital accounts is set to benefit disproportionately when Brazil enters its next rate-cut cycle. At a $2.53B market cap, single-digit P/E and a yield near 0.44%, the stock offers an asymmetric risk-reward for a long-term trade timed to monetary easing.
<p>Embraer is showing the operational footprints and order momentum that can re-light investor interest. This trade targets a mid-term rebound that captures higher production cadence, services revenue kicking in and sentiment re-rating while keeping a disciplined stop to limit downside.</p>
Brookfield Asset Management (BAM) is trading near $45.87 after a pullback from last year’s highs. The business mixes fee-bearing asset management with growing exposure to renewable and infrastructure cash flows, producing $2.305B in free cash flow and a ~4.1% yield today. Short-term momentum and technicals look noisy, but a structured long trade wi…
ON Semiconductor recently sold off after the $7B Synaptics deal and dilution headline. The market has focused on near-term dilution while under-appreciating two durable, higher-margin end markets forming around 800V-1200V silicon carbide power for AI data centers and the Physical AI transition at the edge. ON's balance sheet, cash flow generation a…
Vita Coco (COCO) is the clear leader in U.S. coconut water with ~51-52% share, growing top-line and margins while guiding higher for 2026. The shares have pulled back into an attractive setup after momentum cooled; this trade buys a proven category leader at a defensible price with a clear stop and target.
Voyager Therapeutics has moved beyond single-program risk into a platform story: new AAV capsids that penetrate the blood-brain barrier, multiple Alzheimer’s-focused assets, and a stretched but still visible cash runway. The technicals and short-interest dynamics make a defined-risk long trade attractive over the next ~45 trading days, but executio…
CVR Energy ($CVI) trades at an enterprise value of ~$4.14B and an EV/EBITDA of 7.1x. With free cash flow of $68M last reported and a modest $0.10 quarterly distribution, CVR is a cash-generative refiner exposed to crack spread dynamics. We see a mid-term trade to capture underpriced margin upside as product-crude spreads remain elevated and refiner…
ENI S.p.A. is executing a pragmatic diversification strategy: growing gas and LNG optionality, expanding power & renewables, and adding meaningful exploration wins. At $46.87 the stock offers a 3.7% yield, modest valuation and earnings leverage to recent discoveries. This trade idea targets upside as project deliveries and commercial gas contracts …
Adobe has been hammered in 2026, but the business still throws off massive free cash flow, trades at low-teens earnings multiples and is rolling out meaningful AI product upgrades. This trade idea targets a mid-term rebound into valuation normalization while defining risk tightly below a clean structural low.
Sphere Entertainment (SPHR) is a high-profile theater and media operator that has drawn heavy short activity. Fundamentals show real cash generation and tangible re-rating potential while technicals and short-volume data suggest a squeeze-ready setup. This trade idea lays out an actionable long with entry, stop and target and a balanced view of cat…
I’m maintaining a Buy on Neurocrine (NBIX) after the $2.9B Soleno deal. The acquisition brings Vykat XR ($190M in 2025 revenue) into a company with $831M of free cash flow and a $17.3B market cap, leaving room for operational synergies and multiple expansion. This trade idea lays out entry, stop, target, horizon and the key catalysts and risks to m…
Amazon pulled back in June as investors fretted about ramping AI infrastructure spending. The pullback creates a sensible entry for a mid-term trade: AWS still growing, operating returns remain high, and the balance sheet can carry elevated capex. This idea lays out an entry, stop and target with catalysts and a risk framework.
Elevra Lithium (ELVR) is trading at a discount to its potential as it pivots to North American hard-rock assets after a $71M sale of its Ewoyaa interest. The company is funded to advance Quebec and U.S. projects, and a recovering lithium market combined with tight floats and declining short interest sets up an asymmetric risk/reward. This is a posi…
KKR trades near $93.50 with a market cap around $84B but carries private assets and new AI infrastructure initiatives that management can monetize. We upgrade to Buy because current valuation, cash flow optionality and recent strategic moves make upside to our $122.50 target compelling while risks (liquidity, private credit stress, technicals) rema…
Birkenstock has delivered mid-teens constant-currency revenue growth and management has leaned into buybacks after refinancing. At a $8.31B market cap and ~19.8x trailing earnings, the shares look undervalued relative to the growth profile. This trade plan targets a re-rating back toward 22-24x over the next 45 trading days while keeping risk tight…
NervGen is a clinical-stage biotech focused on NVG-291 for spinal cord repair. A $60M public offering in late May significantly extends runway, management continuity has improved with Adam Rogers as CEO, and short interest/volume dynamics leave room for a mid-term rebound. I recommend a controlled long with defined entry, stop and target framed to …
